Revvity

RVTY Health Care Market cap $14.3B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 6 – Jul 5, 2026 reported Aug 11, 2026

Revenue$0.73B +1% year over year

Gross profit$0.42B 57% margin

Operating profit$0.09B 12% margin

Net profit$0.05B 7% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jul 5, 2026).
Item	Value	Share of revenue	Year over year
Revenue	0.73	100%	+1%
Life sciences	0.36	49%	−1%
Diagnostics	0.35	48%	−1%
Other	0.02	3%
Cost of revenue	−0.31	43%
Gross profit	0.42	57% margin	+3pp
R&D	−0.05	7%	−1pp
SG&A	−0.28	38%	+4pp
Operating profit	0.09	12% margin
Interest & other costs	−0.03
Tax	−0.01
Net profit	0.05	7% margin	+0pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Apr 5, 2026).
Item	Value	Share of revenue	Year over year
Revenue	0.71	100%	+7%
Life sciences	0.36	51%	+6%
Diagnostics	0.35	49%	+8%
Cost of revenue	−0.32	45%
Gross profit	0.39	55% margin	−2pp
R&D	−0.06	8%	+0pp
SG&A	−0.25	36%	−2pp
Operating profit	0.08	11% margin	+0pp
Interest & other costs	−0.03
Tax	−0.01
Net profit	0.04	6% margin	−1pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 28, 2025).
Item	Value	Share of revenue	Year over year
Revenue	0.77	100%	+6%
Diagnostics	0.39	51%	+10%
Life sciences	0.38	49%	+2%
Cost of revenue	−0.35	45%
Gross profit	0.42	55% margin	−2pp
R&D	−0.06	7%	+1pp
SG&A	−0.25	33%	−1pp
Operating profit	0.11	14% margin	−2pp
Interest & other costs	−0.02
Tax benefit	<0.01
Net profit	0.10	13% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 28, 2025).
Item	Value	Share of revenue	Year over year
Revenue	0.70	100%	+2%
Diagnostics	0.36	51%	+3%
Life sciences	0.34	49%	+1%
Cost of revenue	−0.32	46%
Gross profit	0.38	54% margin	−3pp
R&D	−0.05	7%	+0pp
SG&A	−0.24	35%	+0pp
Operating profit	0.08	12% margin	−3pp
Interest & other costs	−0.03
Tax	−0.01
Net profit	0.05	7% margin	−7pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 29, 2025).
Item	Value	Share of revenue	Year over year
Revenue	0.72	100%	+4%
Life sciences	0.37	51%	+5%
Diagnostics	0.35	49%	+3%
Cost of revenue	−0.33	46%
Gross profit	0.39	55% margin	−1pp
R&D	−0.05	7%	+0pp
SG&A	−0.25	35%	−2pp
Operating profit	0.09	13% margin	+0pp
Interest & other costs	−0.02
Tax	−0.01
Net profit	0.05	7% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 6 – Jul 5, 2026 reported Aug 11, 2026 Operating margin 12% Net profit $0.05B	Apr 6 – Jul 5, 2026	Aug 11, 2026	$0.73B	+1%	12%	$0.05B	7%
Q1 FY26 Dec 29, 2025 – Apr 5, 2026 reported May 12, 2026 Operating margin 11% Net profit $0.04B	Dec 29, 2025 – Apr 5, 2026	May 12, 2026	$0.71B	+7%	11%	$0.04B	6%
Q4 FY25 Sep 29 – Dec 28, 2025 reported Feb 24, 2026 Operating margin 14% Net profit $0.10B	Sep 29 – Dec 28, 2025	Feb 24, 2026	$0.77B	+6%	14%	$0.10B	13%
Q3 FY25 Jun 30 – Sep 28, 2025 reported Nov 4, 2025 Operating margin 12% Net profit $0.05B	Jun 30 – Sep 28, 2025	Nov 4, 2025	$0.70B	+2%	12%	$0.05B	7%
Q2 FY25 Mar 31 – Jun 29, 2025 reported Aug 5, 2025 Operating margin 13% Net profit $0.05B	Mar 31 – Jun 29, 2025	Aug 5, 2025	$0.72B	+4%	13%	$0.05B	7%